In 2000, the Food and Drug Administration (FDA) approved thermal ablation, delivered by laser or radiofrequency, which was established as the new gold standard for treating varicose vein disease.
VenaSeal, manufactured by Medtronic, was FDA approved in 2015 to treat varicose veins using medical adhesive as opposed to thermal or heat energy to internally close the superficial vein. This treatment gives patients another option for minimally invasive care.
Candidates for VenaSeal
Ideal candidates are individuals with symptomatic varicose vein disease (leg swelling, pain, heaviness, easy fatigue of the legs, muscle cramping, venous leg ulceration) who have not found relief with conservative treatment. Patients will need a consultation and ultrasound of the legs to determine whether they have venous insufficiency.
Patient benefits
- Allows the patient to avoid anesthesia for the procedure. Most patients feel little, if any, pain during the outpatient procedure.
- Does not require compression hose after surgery.
- Symptoms caused by the diseased superficial vein may improve as soon as the diseased vein is closed.
- Reduced recovery time compared to traditional treatment. Many patients return to normal activity immediately after the procedure.
About varicose veins
These twisted, enlarged veins bulge near the skin’s surface can develop anywhere in the body, but are most commonly found in the legs. Varicose veins can be hereditary or caused by prolonged standing, pregnancy, obesity, menopause and other health concerns.
Many people believe varicose veins are only a cosmetic concern and do not require medical attention. However, untreated varicose veins can lead to venous ulcers, blood clots or deep vein thrombosis, and edema. Other issues include pain, swelling, and tired and achy legs that can get worse if left untreated.
Payment
MercyCare, Blue Cross Blue Shield and Medicare cover the VenaSeal Closure System procedure.